Morgan Stanley maintains Eli Lilly at Overweight
Morgan Stanley maintained its Overweight rating on Eli Lilly, as cited in a ratings-action summary.
Story updates
02:42:40 PM UTC
SquawkNews
Eli Lilly Price Target Raised to $1430.00/Share From $1419.00 by Morgan Stanley